Initial treatment for advanced tumorsexploits the dependence of PCa cells on androgens by combining androgen-deprivationtherapy (ADT) with direct targeting of the androgen receptor (AR),2,3 but many patients stop responding and develop castrate-resistantprostate cancer (CRPC). The gene discussed is AR; the disease is cancer.